×
Hero Background
English
Chinese
French
Japanese
Korean
German
Spanish

Mild Cognitive Impairment Market Analysis

ID: MRFR/HC/9432-CR
151 Pages
Rahul Gotadki
May 2024

Mild Cognitive Impairment Market Research Report By Disease Type (Amnestic MCI and Non-Amnestic MCI), By Age (Child, Adult, Geriatric), By Indication (Lewy Body Dementia, Parkinson’s Disease Dementia, Alzheimer’s Disease, Vascular Dementia, and Others) By Treatment (Medication (Cholinesterase Inhibitors, Benzodiazepines, Glutamate Inhibitors, Antihistamines, Mao Inhibitors, Proton Pump Inhibitors, and Others), Therapy (Cognitive Stimulation Therapy, Cognitive Behavioural Therapy (CBT)), And By Region (North America, Europe, Asia-Pacific, And... read more

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Mild Cognitive Impairment Market Infographic
Request Free Sample
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF

Market Analysis

In-depth Analysis of Mild Cognitive Impairment Market Industry Landscape

The world's aging population has a big effect on the growth of MCI's business. Minor cognitive disability is going up because more people are living longer. So, we need tools for diagnosis, treatments, and support services.

Changes in the market and early detection of mild cognitive impairment are connected. Diagnostic tools and methods allow for early identification. If mild cognitive impairment (MCI) is found early, steps can be taken right away to slow down cognitive decline and improve health.

Biomarkers are very important for diagnosing MCI. Finding and confirming biomarkers like amyloid-beta and tau proteins could change the market by making it easier to diagnose and keep an eye on people with mild cognitive impairment, especially in clinical studies and study. Pharmaceutical research and development has an effect on how the MCI market works. Companies make drugs that stop or slow down neurotoxicity and cognitive decline so that cognitive impairment doesn't get worse. This is to find cures. Education for patients and caregivers has an effect on the field. Educational classes can help people make better decisions, be more aware, and follow through with their treatment. This is very important because it can be hard to understand and deal with mild cognitive decline. The MCI market is changing because of cognitive testing tool technology. Virtual exams, cognitive tests, and digital platforms driven by AI all make diagnostics faster and easier to get, so problems can be found and treated earlier. The prices of healthcare and caregiving for people with moderate cognitive impairment change the way markets work. Market trends are being changed by people who are trying to find MCI treatments and strategies that are both successful and low-cost. Patients with mild cognitive impairment are being used as major subjects in more and more clinical studies. This means including patients' thoughts, opinions, and activities in the planning of clinical trials. This shows that the market is changing toward research that is more open and focused on patients. Market patterns are being changed by programs that aim to stop cognitive decline and improve brain health. These projects are getting bigger. These efforts aim to improve the protection and treatment of mild cognitive decline by focusing on changes to living, managing risk factors, and events in the community. The business of helping people with mild cognitive decline is expected to grow as new technologies come out. In the future, there may be digital health solutions for constant tracking, focused drugs based on personalized risk profiles, and better diagnosis criteria. As science and understanding grow, the market for mild cognitive impairment treatment and control will change.

Author
Rahul Gotadki
Assistant Manager

He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

Get In Touch

Leave a Comment

FAQs

What is the current valuation of the Mild Cognitive Impairment Market as of 2024?

The overall market valuation was 2.05 USD Billion in 2024.

What is the projected market valuation for Mild Cognitive Impairment by 2035?

The projected valuation for 2035 is 3.872 USD Billion.

What is the expected CAGR for the Mild Cognitive Impairment Market during the forecast period 2025 - 2035?

The expected CAGR for the market during this period is 5.95%.

Which companies are considered key players in the Mild Cognitive Impairment Market?

Key players include Eli Lilly and Company, Biogen Inc., Pfizer Inc., Novartis AG, AstraZeneca PLC, Roche Holding AG, Merck & Co., Inc., Johnson & Johnson, and Amgen Inc.

How is the Mild Cognitive Impairment Market segmented by disease type?

The market segments by disease type include Amnestic MCI valued at 1.23 to 2.25 USD Billion and Non-Amnestic MCI valued at 0.82 to 1.62 USD Billion.

Market Summary

As per MRFR analysis, the Mild Cognitive Impairment Market Size was estimated at 2.05 USD Billion in 2024. The Mild Cognitive Impairment industry is projected to grow from 2.172 USD Billion in 2025 to 3.872 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 5.95 during the forecast period 2025 - 2035.

Key Market Trends & Highlights

The Mild Cognitive Impairment Market is experiencing transformative growth driven by technological advancements and increasing awareness.

  • Technological advancements in diagnostics are enhancing early detection and intervention strategies in the Mild Cognitive Impairment Market.
  • Personalized treatment approaches are gaining traction, particularly in the Amnestic MCI segment, which remains the largest market segment.
  • Increased awareness and education about cognitive health are contributing to a growing demand for services in North America, the largest market.
  • The aging population and rising incidence of cognitive disorders, coupled with advancements in neuroimaging techniques, are key drivers propelling market growth.

Market Size & Forecast

2024 Market Size 2.05 (USD Billion)
2035 Market Size 3.872 (USD Billion)
CAGR (2025 - 2035) 5.95%
Largest Regional Market Share in 2024 North America

Major Players

<p>Eli Lilly and Company (US), Biogen Inc. (US), Pfizer Inc. (US), Novartis AG (CH), AstraZeneca PLC (GB), Roche Holding AG (CH), Merck & Co., Inc. (US), Johnson & Johnson (US), Amgen Inc. (US)</p>

Market Trends

The Mild Cognitive Impairment Market is currently experiencing a notable evolution, driven by an increasing awareness of cognitive health and the need for early diagnosis. As the global population ages, the prevalence of mild cognitive impairment is becoming more pronounced, prompting healthcare systems to prioritize cognitive assessments. This shift is likely to enhance the demand for diagnostic tools and therapeutic interventions tailored to this condition. Furthermore, advancements in technology, particularly in neuroimaging and digital health solutions, appear to be facilitating more accurate and timely diagnoses, which could lead to improved patient outcomes. In addition, the Mild Cognitive Impairment Market is witnessing a growing emphasis on personalized treatment approaches. Healthcare providers are increasingly recognizing that cognitive impairment is not a one-size-fits-all condition. As a result, there is a trend towards developing individualized care plans that consider the unique needs of each patient. This personalized approach may enhance the effectiveness of interventions and foster better engagement from patients and caregivers alike. Overall, the Mild Cognitive Impairment Market is poised for growth, driven by technological advancements and a deeper understanding of cognitive health.

Technological Advancements in Diagnostics

The Mild Cognitive Impairment Market is seeing a surge in the adoption of advanced diagnostic technologies. Innovations in neuroimaging and artificial intelligence are enhancing the accuracy of assessments, allowing for earlier detection of cognitive decline. These developments may lead to more effective treatment strategies and improved patient management.

Personalized Treatment Approaches

There is a growing trend towards personalized treatment plans within the Mild Cognitive Impairment Market. Healthcare professionals are increasingly tailoring interventions to meet the specific needs of individuals, which could result in better outcomes and higher patient satisfaction. This shift emphasizes the importance of understanding the unique characteristics of each case.

Increased Awareness and Education

The Mild Cognitive Impairment Market is benefiting from heightened awareness and educational initiatives aimed at both healthcare providers and the general public. As knowledge about cognitive health expands, more individuals are seeking early assessments and interventions, potentially leading to a larger market for related services and products.

Mild Cognitive Impairment Market Market Drivers

Increased Focus on Mental Health

The heightened focus on mental health and cognitive wellness is driving the Mild Cognitive Impairment Market. Societal attitudes towards mental health have evolved, leading to greater acceptance and understanding of cognitive disorders. This shift has resulted in increased funding for mental health initiatives and awareness campaigns aimed at educating the public about mild cognitive impairment. As awareness grows, more individuals are seeking evaluation and treatment for cognitive issues, which is likely to boost demand for services and products within the Mild Cognitive Impairment Market. Additionally, healthcare providers are prioritizing mental health as a critical component of overall health, further propelling the market forward.

Aging Population and Rising Incidence

The aging population is a primary driver of the Mild Cognitive Impairment Market. As individuals age, the prevalence of cognitive decline increases, with studies indicating that approximately 15 to 20% of older adults experience mild cognitive impairment. This demographic shift is expected to continue, leading to a higher demand for diagnostic and therapeutic solutions within the Mild Cognitive Impairment Market. Furthermore, the World Health Organization projects that the number of people aged 60 years and older will double from 12% to 22% by 2050, further emphasizing the need for effective management strategies for cognitive health. Consequently, healthcare systems are increasingly focusing on early detection and intervention, which could potentially enhance the quality of life for affected individuals.

Advancements in Neuroimaging Techniques

Recent advancements in neuroimaging techniques are significantly influencing the Mild Cognitive Impairment Market. Technologies such as MRI and PET scans have improved the ability to detect early signs of cognitive decline, allowing for timely diagnosis and intervention. These innovations not only enhance the accuracy of assessments but also facilitate the differentiation between mild cognitive impairment and other neurodegenerative disorders. As a result, healthcare providers are more equipped to tailor treatment plans to individual needs, which is crucial in managing mild cognitive impairment effectively. The increasing adoption of these advanced imaging modalities is likely to drive market growth, as they become integral to clinical practice and research in the Mild Cognitive Impairment Market.

Integration of Digital Health Solutions

The integration of digital health solutions is emerging as a transformative driver in the Mild Cognitive Impairment Market. Telehealth platforms and mobile applications are increasingly being utilized to monitor cognitive health and provide support for individuals with mild cognitive impairment. These digital tools offer convenient access to healthcare professionals and resources, enabling timely interventions and ongoing management of cognitive health. Moreover, the use of artificial intelligence and machine learning in these solutions is enhancing the ability to analyze cognitive data, leading to more personalized care. As the adoption of digital health solutions continues to rise, it is expected to significantly impact the Mild Cognitive Impairment Market, improving accessibility and patient engagement.

Growing Investment in Research and Development

Investment in research and development is a critical driver of the Mild Cognitive Impairment Market. Pharmaceutical companies and research institutions are increasingly allocating resources to explore novel therapeutic options and interventions for mild cognitive impairment. This trend is evidenced by the rising number of clinical trials aimed at evaluating new drugs and treatment modalities. According to recent data, the number of clinical trials focused on cognitive impairment has seen a substantial increase, reflecting a growing recognition of the condition's impact on public health. As these investments yield promising results, they are likely to lead to the introduction of innovative therapies, thereby expanding the Mild Cognitive Impairment Market and improving patient outcomes.

Market Segment Insights

Mild Cognitive Impairment Market Disease Type Insights

<p>The Mild Cognitive Impairment Market segmentation, based on disease type, amnestic MCI and non-amnestic MCI. The amnestic MCI segment dominated the market in 2022 and is projected to be the fastest-growing during the forecast period, 2023–2032. Amnestic Mild Cognitive Impairment Market (MCI) is a subtype of MCI characterized by memory deficits beyond what is expected for a person's age but not severe enough to meet the criteria for dementia.</p>

<p>Individuals with amnestic MCI typically exhibit memory impairment that is greater than expected for their age and educational level but do not show significant impairments in other cognitive domains such as language, executive function, or visuospatial skills. Amnestic MCI is considered a transitional stage between normal aging and dementia, particularly Alzheimer's disease. Research suggests that individuals with amnestic MCI have an increased risk of progressing to Alzheimer's disease or other forms of dementia compared to those without cognitive impairment.</p>

<p>Figure 2: Mild Cognitive Impairment Market, by Disease Type, 2023 &amp; 2032 (USD Billion)</p>

Mild Cognitive Impairment Market Age Insights

<p>The mild cognitive impairment market segmentation, based on age, includes child, adult, and geriatric. The geriatric segment dominated the market in 2022 and adult is projected to be the fastest-growing during the forecast period, 2023–2032. Mild cognitive impairment (MCI) in geriatric individuals, particularly those aged 65 and older, is a common concern in clinical settings. For instance, Globally, the prevalence of cognitive impairment in individuals aged 50 years or older ranges from 5.1 to 41.0%, with a median of 19.0%. In children, mild cognitive impairment may manifest as difficulties in learning, memory, attention, executive functions, or language skills.</p>

<p>Some potential causes include genetic factors, prenatal exposure to toxins or infections, perinatal complications, traumatic brain injury, neurodevelopmental disorders like autism spectrum disorder or attention deficit hyperactivity disorder (ADHD), and certain medical conditions affecting brain development.</p>

Mild Cognitive Impairment Market Indication Insights

<p>The Mild Cognitive Impairment Market has been segmented, based on indication into Lewy body dementia, Parkinson’s disease dementia, Alzheimer’s disease, vascular dementia, and others. The Alzheimer’s disease segment dominated the market in 2022 and Parkinson’s disease dementia is projected to be the fastest-growing during the forecast period, 2023–2032. Alzheimer's disease is a progressive neurodegenerative disorder that primarily affects memory, cognition, and behavior. It is the most common cause of dementia among older adults. For instance, more than 6 million Americans of all ages suffer with Alzheimer's disease.</p>

<p>In 2023, an estimated 6.7 million Americans aged 65 and older were living with Alzheimer's. Seventy-three percent are aged 75 or older. Alzheimer's affects around one in every nine adults aged 65 and older (10.7%). Alzheimer's disease typically begins with subtle memory loss and progresses to include confusion, disorientation, and difficulty with language, reasoning, and problem-solving. Lewy body dementia (LBD) is a type of dementia characterized by the presence of abnormal protein deposits called Lewy bodies in the brain. These deposits disrupt the normal functioning of brain cells, leading to cognitive impairment, changes in behavior, and other symptoms.</p>

<p>Cognitive impairment in LBD can manifest as difficulties with memory, reasoning, problem-solving, and other cognitive functions.</p>

Mild Cognitive Impairment Market Treatment Insights

<p>The Mild Cognitive Impairment Market has been segmented into medication and therapy. The medication segment dominated the market in 2022 and therapy is projected to be the fastest-growing during the forecast period, 2023–2032. Cognitive impairment can result from various underlying conditions such as Alzheimer's disease, vascular dementia, mild cognitive impairment, etc. Treatment options depend on the cause and severity of the impairment. Cognitive Stimulation Therapy (CST) is an evidence-based psychosocial intervention designed to improve cognitive function, quality of life, and well-being in people with cognitive impairment, particularly those with dementia.</p>

<p>CST is typically delivered in a group format and involves a variety of activities and discussions aimed at stimulating cognitive abilities and social interaction. Cognitive Behavioral Therapy (CBT) has primarily been developed and utilized to treat various mental health conditions such as depression, anxiety disorders, and PTSD. However, there's been growing interest and some research in using CBT techniques to address cognitive impairment, particularly in populations like older adults or individuals with neurological conditions such as mild cognitive impairment (MCI) or dementia.</p>

Get more detailed insights about Mild Cognitive Impairment Market Research Report - Global Forecast till 2035

Regional Insights

North America : Leading Market for Innovation

North America is the largest market for Mild Cognitive Impairment Market (MCI) therapies, accounting for approximately 45% of the global market share. The region benefits from advanced healthcare infrastructure, significant R&D investments, and a growing elderly population. Regulatory support from agencies like the FDA has catalyzed the development of innovative treatments, driving demand for effective solutions in managing MCI. The United States is the primary contributor, with key players such as Eli Lilly, Biogen, and Pfizer leading the charge in research and product development. Canada also plays a significant role, focusing on early diagnosis and intervention strategies. The competitive landscape is characterized by collaborations between pharmaceutical companies and research institutions, enhancing the pipeline of MCI therapies.

Europe : Emerging Regulatory Frameworks

Europe is witnessing a significant rise in the Mild Cognitive Impairment Market, holding approximately 30% of the global share. The region's growth is driven by increasing awareness of cognitive health, supportive regulatory frameworks, and a focus on preventive healthcare. Countries like Germany and France are at the forefront, implementing policies that encourage research and development in cognitive disorders, thus enhancing market dynamics. Germany leads the European market, supported by a robust healthcare system and a strong presence of pharmaceutical giants like Novartis and Roche. The competitive landscape is evolving, with a mix of established players and emerging biotech firms focusing on innovative therapies. Collaborative efforts between governments and private sectors are fostering advancements in MCI treatment options, ensuring a comprehensive approach to cognitive health.

Asia-Pacific : Rapidly Expanding Market Potential

The Asia-Pacific region is rapidly emerging as a significant player in the Mild Cognitive Impairment Market, accounting for about 20% of the global share. Factors such as an aging population, increasing healthcare expenditure, and rising awareness of cognitive health are driving this growth. Countries like Japan and China are leading the charge, with government initiatives aimed at improving mental health services and access to treatments for MCI. Japan is particularly notable for its advanced healthcare system and strong pharmaceutical industry, with companies like Takeda and Astellas actively involved in MCI research. The competitive landscape is characterized by a mix of local and international players, fostering innovation and collaboration. As the region continues to develop its healthcare infrastructure, the demand for effective MCI therapies is expected to rise significantly.

Middle East and Africa : Emerging Market with Challenges

The Middle East and Africa region is gradually developing its Mild Cognitive Impairment Market, currently holding about 5% of the global share. The growth is driven by increasing awareness of cognitive health issues and a rising elderly population. However, challenges such as limited healthcare infrastructure and access to treatments hinder rapid market expansion. Countries like South Africa and the UAE are making strides in improving mental health services and awareness campaigns. South Africa is leading the market in the region, with initiatives aimed at enhancing cognitive health services. The competitive landscape is still in its nascent stages, with a few local players and international companies exploring opportunities. Collaborative efforts between governments and NGOs are essential to address the challenges and improve access to MCI therapies, paving the way for future growth.

Key Players and Competitive Insights

The Mild Cognitive Impairment Market is distinguished by the presence of numerous regional and local players catering to mild cognitive impairment market products that are evolving at a rapid pace. Furthermore, the increasing burden of mild cognitive impairment across the globe and rising awareness associated with mild cognitive impairment in the healthcare industry is further driving the growth of Mild Cognitive Impairment Market during the forecast period. The major players have adopted a strategy of obtaining regulatory approval from government agencies for their products and signing contracts and agreements to broaden their reach.

Eisai Co., Ltd. manufactures prescription drugs and medical equipment and primarily sells to sales agents and subsidiaries. They aim to provide services for a risk prediction algorithm for early detection of mild cognitive impairment (MCI) and dementia.

In January 2023, Eisai Co., Ltd. (Japan) announced that the FDA granted accelerated approval to LEQEMBI (lecanemab-irmb), a treatment for early AD.

Key Companies in the Mild Cognitive Impairment Market market include

Industry Developments

  • January 2023, Biogen (US) announced that the FDA granted accelerated approval to LEQEMBI (lecanemab-irmb), a treatment for early AD developed in collaboration with Eisai Co., Ltd (Japan).

Future Outlook

Mild Cognitive Impairment Market Future Outlook

<p>The Mild Cognitive Impairment Market is projected to grow at a 5.95% CAGR from 2024 to 2035, driven by increasing awareness, technological advancements, and rising geriatric populations.</p>

New opportunities lie in:

  • <p>Development of digital cognitive training platforms for remote patient engagement.</p>
  • <p>Expansion of biomarker-based diagnostic tools for early detection.</p>
  • <p>Investment in telehealth services tailored for cognitive assessments.</p>

<p>By 2035, the Mild Cognitive Impairment Market is expected to be robust, reflecting substantial growth and innovation.</p>

Market Segmentation

Mild Cognitive Impairment Market Age Outlook

  • Child
  • Adult
  • Geriatric

Mild Cognitive Impairment Market Treatment Outlook

  • Medication
  • Therapy

Mild Cognitive Impairment Market Indication Outlook

  • Lewy Body Dementia
  • Parkinson's Disease Dementia
  • Alzheimer’s Disease
  • Vascular Dementia
  • Others

Mild Cognitive Impairment Market Disease Type Outlook

  • Amnestic MCI
  • Non-Amnestic MCI

Report Scope

MARKET SIZE 20242.05(USD Billion)
MARKET SIZE 20252.172(USD Billion)
MARKET SIZE 20353.872(USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR)5.95% (2024 - 2035)
REPORT COVERAGERevenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR2024
Market Forecast Period2025 - 2035
Historical Data2019 - 2024
Market Forecast UnitsUSD Billion
Key Companies ProfiledMarket analysis in progress
Segments CoveredMarket segmentation analysis in progress
Key Market OpportunitiesAdvancements in digital therapeutics enhance patient engagement in the Mild Cognitive Impairment Market.
Key Market DynamicsRising demand for innovative therapies drives competitive forces in the Mild Cognitive Impairment market.
Countries CoveredNorth America, Europe, APAC, South America, MEA

FAQs

What is the current valuation of the Mild Cognitive Impairment Market as of 2024?

The overall market valuation was 2.05 USD Billion in 2024.

What is the projected market valuation for Mild Cognitive Impairment by 2035?

The projected valuation for 2035 is 3.872 USD Billion.

What is the expected CAGR for the Mild Cognitive Impairment Market during the forecast period 2025 - 2035?

The expected CAGR for the market during this period is 5.95%.

Which companies are considered key players in the Mild Cognitive Impairment Market?

Key players include Eli Lilly and Company, Biogen Inc., Pfizer Inc., Novartis AG, AstraZeneca PLC, Roche Holding AG, Merck & Co., Inc., Johnson & Johnson, and Amgen Inc.

How is the Mild Cognitive Impairment Market segmented by disease type?

The market segments by disease type include Amnestic MCI valued at 1.23 to 2.25 USD Billion and Non-Amnestic MCI valued at 0.82 to 1.62 USD Billion.

  1. SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. EXECUTIVE SUMMARY
      1. Market Overview
      2. Key Findings
      3. Market Segmentation
      4. Competitive Landscape
      5. Challenges and Opportunities
      6. Future Outlook
  2. SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. MARKET INTRODUCTION
      1. Definition
      2. Scope of the study
    2. RESEARCH METHODOLOGY
      1. Overview
      2. Data Mining
      3. Secondary Research
      4. Primary Research
      5. Forecasting Model
      6. Market Size Estimation
      7. Data Triangulation
      8. Validation
  3. SECTION III: QUALITATIVE ANALYSIS
    1. MARKET DYNAMICS
      1. Overview
      2. Drivers
      3. Restraints
      4. Opportunities
    2. MARKET FACTOR ANALYSIS
      1. Value chain Analysis
      2. Porter's Five Forces Analysis
      3. COVID-19 Impact Analysis
  4. SECTION IV: QUANTITATIVE ANALYSIS
    1. Healthcare, BY Disease Type (USD Billion)
      1. Amnestic MCI
      2. Non-Amnestic MCI
    2. Healthcare, BY Age (USD Billion)
      1. Child
      2. Adult
      3. Geriatric
    3. Healthcare, BY Indication (USD Billion)
      1. Lewy Body Dementia
      2. Parkinson's Disease Dementia
      3. Alzheimer’s Disease
      4. Vascular Dementia
      5. Others
    4. Healthcare, BY Treatment (USD Billion)
      1. Medication
      2. Therapy
    5. Healthcare, BY Region (USD Billion)
      1. North America
      2. Europe
      3. APAC
      4. South America
      5. MEA
  5. SECTION V: COMPETITIVE ANALYSIS
    1. Competitive Landscape
      1. Overview
      2. Competitive Analysis
      3. Market share Analysis
      4. Major Growth Strategy in the Healthcare
      5. Competitive Benchmarking
      6. Leading Players in Terms of Number of Developments in the Healthcare
      7. Key developments and growth strategies
      8. Major Players Financial Matrix
    2. Company Profiles
      1. Eli Lilly and Company (US)
      2. Biogen Inc. (US)
      3. Pfizer Inc. (US)
      4. Novartis AG (CH)
      5. AstraZeneca PLC (GB)
      6. Roche Holding AG (CH)
      7. Merck & Co., Inc. (US)
      8. Johnson & Johnson (US)
      9. Amgen Inc. (US)
    3. Appendix
      1. References
      2. Related Reports
  6. LIST OF FIGURES
    1. MARKET SYNOPSIS
    2. NORTH AMERICA MARKET ANALYSIS
    3. US MARKET ANALYSIS BY DISEASE TYPE
    4. US MARKET ANALYSIS BY AGE
    5. US MARKET ANALYSIS BY INDICATION
    6. US MARKET ANALYSIS BY TREATMENT
    7. CANADA MARKET ANALYSIS BY DISEASE TYPE
    8. CANADA MARKET ANALYSIS BY AGE
    9. CANADA MARKET ANALYSIS BY INDICATION
    10. CANADA MARKET ANALYSIS BY TREATMENT
    11. EUROPE MARKET ANALYSIS
    12. GERMANY MARKET ANALYSIS BY DISEASE TYPE
    13. GERMANY MARKET ANALYSIS BY AGE
    14. GERMANY MARKET ANALYSIS BY INDICATION
    15. GERMANY MARKET ANALYSIS BY TREATMENT
    16. UK MARKET ANALYSIS BY DISEASE TYPE
    17. UK MARKET ANALYSIS BY AGE
    18. UK MARKET ANALYSIS BY INDICATION
    19. UK MARKET ANALYSIS BY TREATMENT
    20. FRANCE MARKET ANALYSIS BY DISEASE TYPE
    21. FRANCE MARKET ANALYSIS BY AGE
    22. FRANCE MARKET ANALYSIS BY INDICATION
    23. FRANCE MARKET ANALYSIS BY TREATMENT
    24. RUSSIA MARKET ANALYSIS BY DISEASE TYPE
    25. RUSSIA MARKET ANALYSIS BY AGE
    26. RUSSIA MARKET ANALYSIS BY INDICATION
    27. RUSSIA MARKET ANALYSIS BY TREATMENT
    28. ITALY MARKET ANALYSIS BY DISEASE TYPE
    29. ITALY MARKET ANALYSIS BY AGE
    30. ITALY MARKET ANALYSIS BY INDICATION
    31. ITALY MARKET ANALYSIS BY TREATMENT
    32. SPAIN MARKET ANALYSIS BY DISEASE TYPE
    33. SPAIN MARKET ANALYSIS BY AGE
    34. SPAIN MARKET ANALYSIS BY INDICATION
    35. SPAIN MARKET ANALYSIS BY TREATMENT
    36. REST OF EUROPE MARKET ANALYSIS BY DISEASE TYPE
    37. REST OF EUROPE MARKET ANALYSIS BY AGE
    38. REST OF EUROPE MARKET ANALYSIS BY INDICATION
    39. REST OF EUROPE MARKET ANALYSIS BY TREATMENT
    40. APAC MARKET ANALYSIS
    41. CHINA MARKET ANALYSIS BY DISEASE TYPE
    42. CHINA MARKET ANALYSIS BY AGE
    43. CHINA MARKET ANALYSIS BY INDICATION
    44. CHINA MARKET ANALYSIS BY TREATMENT
    45. INDIA MARKET ANALYSIS BY DISEASE TYPE
    46. INDIA MARKET ANALYSIS BY AGE
    47. INDIA MARKET ANALYSIS BY INDICATION
    48. INDIA MARKET ANALYSIS BY TREATMENT
    49. JAPAN MARKET ANALYSIS BY DISEASE TYPE
    50. JAPAN MARKET ANALYSIS BY AGE
    51. JAPAN MARKET ANALYSIS BY INDICATION
    52. JAPAN MARKET ANALYSIS BY TREATMENT
    53. SOUTH KOREA MARKET ANALYSIS BY DISEASE TYPE
    54. SOUTH KOREA MARKET ANALYSIS BY AGE
    55. SOUTH KOREA MARKET ANALYSIS BY INDICATION
    56. SOUTH KOREA MARKET ANALYSIS BY TREATMENT
    57. MALAYSIA MARKET ANALYSIS BY DISEASE TYPE
    58. MALAYSIA MARKET ANALYSIS BY AGE
    59. MALAYSIA MARKET ANALYSIS BY INDICATION
    60. MALAYSIA MARKET ANALYSIS BY TREATMENT
    61. THAILAND MARKET ANALYSIS BY DISEASE TYPE
    62. THAILAND MARKET ANALYSIS BY AGE
    63. THAILAND MARKET ANALYSIS BY INDICATION
    64. THAILAND MARKET ANALYSIS BY TREATMENT
    65. INDONESIA MARKET ANALYSIS BY DISEASE TYPE
    66. INDONESIA MARKET ANALYSIS BY AGE
    67. INDONESIA MARKET ANALYSIS BY INDICATION
    68. INDONESIA MARKET ANALYSIS BY TREATMENT
    69. REST OF APAC MARKET ANALYSIS BY DISEASE TYPE
    70. REST OF APAC MARKET ANALYSIS BY AGE
    71. REST OF APAC MARKET ANALYSIS BY INDICATION
    72. REST OF APAC MARKET ANALYSIS BY TREATMENT
    73. SOUTH AMERICA MARKET ANALYSIS
    74. BRAZIL MARKET ANALYSIS BY DISEASE TYPE
    75. BRAZIL MARKET ANALYSIS BY AGE
    76. BRAZIL MARKET ANALYSIS BY INDICATION
    77. BRAZIL MARKET ANALYSIS BY TREATMENT
    78. MEXICO MARKET ANALYSIS BY DISEASE TYPE
    79. MEXICO MARKET ANALYSIS BY AGE
    80. MEXICO MARKET ANALYSIS BY INDICATION
    81. MEXICO MARKET ANALYSIS BY TREATMENT
    82. ARGENTINA MARKET ANALYSIS BY DISEASE TYPE
    83. ARGENTINA MARKET ANALYSIS BY AGE
    84. ARGENTINA MARKET ANALYSIS BY INDICATION
    85. ARGENTINA MARKET ANALYSIS BY TREATMENT
    86. REST OF SOUTH AMERICA MARKET ANALYSIS BY DISEASE TYPE
    87. REST OF SOUTH AMERICA MARKET ANALYSIS BY AGE
    88. REST OF SOUTH AMERICA MARKET ANALYSIS BY INDICATION
    89. REST OF SOUTH AMERICA MARKET ANALYSIS BY TREATMENT
    90. MEA MARKET ANALYSIS
    91. GCC COUNTRIES MARKET ANALYSIS BY DISEASE TYPE
    92. GCC COUNTRIES MARKET ANALYSIS BY AGE
    93. GCC COUNTRIES MARKET ANALYSIS BY INDICATION
    94. GCC COUNTRIES MARKET ANALYSIS BY TREATMENT
    95. SOUTH AFRICA MARKET ANALYSIS BY DISEASE TYPE
    96. SOUTH AFRICA MARKET ANALYSIS BY AGE
    97. SOUTH AFRICA MARKET ANALYSIS BY INDICATION
    98. SOUTH AFRICA MARKET ANALYSIS BY TREATMENT
    99. REST OF MEA MARKET ANALYSIS BY DISEASE TYPE
    100. REST OF MEA MARKET ANALYSIS BY AGE
    101. REST OF MEA MARKET ANALYSIS BY INDICATION
    102. REST OF MEA MARKET ANALYSIS BY TREATMENT
    103. KEY BUYING CRITERIA OF HEALTHCARE
    104. RESEARCH PROCESS OF MRFR
    105. DRO ANALYSIS OF HEALTHCARE
    106. DRIVERS IMPACT ANALYSIS: HEALTHCARE
    107. RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
    108. SUPPLY / VALUE CHAIN: HEALTHCARE
    109. HEALTHCARE, BY DISEASE TYPE, 2024 (% SHARE)
    110. HEALTHCARE, BY DISEASE TYPE, 2024 TO 2035 (USD Billion)
    111. HEALTHCARE, BY AGE, 2024 (% SHARE)
    112. HEALTHCARE, BY AGE, 2024 TO 2035 (USD Billion)
    113. HEALTHCARE, BY INDICATION, 2024 (% SHARE)
    114. HEALTHCARE, BY INDICATION, 2024 TO 2035 (USD Billion)
    115. HEALTHCARE, BY TREATMENT, 2024 (% SHARE)
    116. HEALTHCARE, BY TREATMENT, 2024 TO 2035 (USD Billion)
    117. BENCHMARKING OF MAJOR COMPETITORS
  7. LIST OF TABLES
    1. LIST OF ASSUMPTIONS
    2. North America MARKET SIZE ESTIMATES; FORECAST
      1. BY DISEASE TYPE, 2025-2035 (USD Billion)
      2. BY AGE, 2025-2035 (USD Billion)
      3. BY INDICATION, 2025-2035 (USD Billion)
      4. BY TREATMENT, 2025-2035 (USD Billion)
    3. US MARKET SIZE ESTIMATES; FORECAST
      1. BY DISEASE TYPE, 2025-2035 (USD Billion)
      2. BY AGE, 2025-2035 (USD Billion)
      3. BY INDICATION, 2025-2035 (USD Billion)
      4. BY TREATMENT, 2025-2035 (USD Billion)
    4. Canada MARKET SIZE ESTIMATES; FORECAST
      1. BY DISEASE TYPE, 2025-2035 (USD Billion)
      2. BY AGE, 2025-2035 (USD Billion)
      3. BY INDICATION, 2025-2035 (USD Billion)
      4. BY TREATMENT, 2025-2035 (USD Billion)
    5. Europe MARKET SIZE ESTIMATES; FORECAST
      1. BY DISEASE TYPE, 2025-2035 (USD Billion)
      2. BY AGE, 2025-2035 (USD Billion)
      3. BY INDICATION, 2025-2035 (USD Billion)
      4. BY TREATMENT, 2025-2035 (USD Billion)
    6. Germany MARKET SIZE ESTIMATES; FORECAST
      1. BY DISEASE TYPE, 2025-2035 (USD Billion)
      2. BY AGE, 2025-2035 (USD Billion)
      3. BY INDICATION, 2025-2035 (USD Billion)
      4. BY TREATMENT, 2025-2035 (USD Billion)
    7. UK MARKET SIZE ESTIMATES; FORECAST
      1. BY DISEASE TYPE, 2025-2035 (USD Billion)
      2. BY AGE, 2025-2035 (USD Billion)
      3. BY INDICATION, 2025-2035 (USD Billion)
      4. BY TREATMENT, 2025-2035 (USD Billion)
    8. France MARKET SIZE ESTIMATES; FORECAST
      1. BY DISEASE TYPE, 2025-2035 (USD Billion)
      2. BY AGE, 2025-2035 (USD Billion)
      3. BY INDICATION, 2025-2035 (USD Billion)
      4. BY TREATMENT, 2025-2035 (USD Billion)
    9. Russia MARKET SIZE ESTIMATES; FORECAST
      1. BY DISEASE TYPE, 2025-2035 (USD Billion)
      2. BY AGE, 2025-2035 (USD Billion)
      3. BY INDICATION, 2025-2035 (USD Billion)
      4. BY TREATMENT, 2025-2035 (USD Billion)
    10. Italy MARKET SIZE ESTIMATES; FORECAST
      1. BY DISEASE TYPE, 2025-2035 (USD Billion)
      2. BY AGE, 2025-2035 (USD Billion)
      3. BY INDICATION, 2025-2035 (USD Billion)
      4. BY TREATMENT, 2025-2035 (USD Billion)
    11. Spain MARKET SIZE ESTIMATES; FORECAST
      1. BY DISEASE TYPE, 2025-2035 (USD Billion)
      2. BY AGE, 2025-2035 (USD Billion)
      3. BY INDICATION, 2025-2035 (USD Billion)
      4. BY TREATMENT, 2025-2035 (USD Billion)
    12. Rest of Europe MARKET SIZE ESTIMATES; FORECAST
      1. BY DISEASE TYPE, 2025-2035 (USD Billion)
      2. BY AGE, 2025-2035 (USD Billion)
      3. BY INDICATION, 2025-2035 (USD Billion)
      4. BY TREATMENT, 2025-2035 (USD Billion)
    13. APAC MARKET SIZE ESTIMATES; FORECAST
      1. BY DISEASE TYPE, 2025-2035 (USD Billion)
      2. BY AGE, 2025-2035 (USD Billion)
      3. BY INDICATION, 2025-2035 (USD Billion)
      4. BY TREATMENT, 2025-2035 (USD Billion)
    14. China MARKET SIZE ESTIMATES; FORECAST
      1. BY DISEASE TYPE, 2025-2035 (USD Billion)
      2. BY AGE, 2025-2035 (USD Billion)
      3. BY INDICATION, 2025-2035 (USD Billion)
      4. BY TREATMENT, 2025-2035 (USD Billion)
    15. India MARKET SIZE ESTIMATES; FORECAST
      1. BY DISEASE TYPE, 2025-2035 (USD Billion)
      2. BY AGE, 2025-2035 (USD Billion)
      3. BY INDICATION, 2025-2035 (USD Billion)
      4. BY TREATMENT, 2025-2035 (USD Billion)
    16. Japan MARKET SIZE ESTIMATES; FORECAST
      1. BY DISEASE TYPE, 2025-2035 (USD Billion)
      2. BY AGE, 2025-2035 (USD Billion)
      3. BY INDICATION, 2025-2035 (USD Billion)
      4. BY TREATMENT, 2025-2035 (USD Billion)
    17. South Korea MARKET SIZE ESTIMATES; FORECAST
      1. BY DISEASE TYPE, 2025-2035 (USD Billion)
      2. BY AGE, 2025-2035 (USD Billion)
      3. BY INDICATION, 2025-2035 (USD Billion)
      4. BY TREATMENT, 2025-2035 (USD Billion)
    18. Malaysia MARKET SIZE ESTIMATES; FORECAST
      1. BY DISEASE TYPE, 2025-2035 (USD Billion)
      2. BY AGE, 2025-2035 (USD Billion)
      3. BY INDICATION, 2025-2035 (USD Billion)
      4. BY TREATMENT, 2025-2035 (USD Billion)
    19. Thailand MARKET SIZE ESTIMATES; FORECAST
      1. BY DISEASE TYPE, 2025-2035 (USD Billion)
      2. BY AGE, 2025-2035 (USD Billion)
      3. BY INDICATION, 2025-2035 (USD Billion)
      4. BY TREATMENT, 2025-2035 (USD Billion)
    20. Indonesia MARKET SIZE ESTIMATES; FORECAST
      1. BY DISEASE TYPE, 2025-2035 (USD Billion)
      2. BY AGE, 2025-2035 (USD Billion)
      3. BY INDICATION, 2025-2035 (USD Billion)
      4. BY TREATMENT, 2025-2035 (USD Billion)
    21. Rest of APAC MARKET SIZE ESTIMATES; FORECAST
      1. BY DISEASE TYPE, 2025-2035 (USD Billion)
      2. BY AGE, 2025-2035 (USD Billion)
      3. BY INDICATION, 2025-2035 (USD Billion)
      4. BY TREATMENT, 2025-2035 (USD Billion)
    22. South America MARKET SIZE ESTIMATES; FORECAST
      1. BY DISEASE TYPE, 2025-2035 (USD Billion)
      2. BY AGE, 2025-2035 (USD Billion)
      3. BY INDICATION, 2025-2035 (USD Billion)
      4. BY TREATMENT, 2025-2035 (USD Billion)
    23. Brazil MARKET SIZE ESTIMATES; FORECAST
      1. BY DISEASE TYPE, 2025-2035 (USD Billion)
      2. BY AGE, 2025-2035 (USD Billion)
      3. BY INDICATION, 2025-2035 (USD Billion)
      4. BY TREATMENT, 2025-2035 (USD Billion)
    24. Mexico MARKET SIZE ESTIMATES; FORECAST
      1. BY DISEASE TYPE, 2025-2035 (USD Billion)
      2. BY AGE, 2025-2035 (USD Billion)
      3. BY INDICATION, 2025-2035 (USD Billion)
      4. BY TREATMENT, 2025-2035 (USD Billion)
    25. Argentina MARKET SIZE ESTIMATES; FORECAST
      1. BY DISEASE TYPE, 2025-2035 (USD Billion)
      2. BY AGE, 2025-2035 (USD Billion)
      3. BY INDICATION, 2025-2035 (USD Billion)
      4. BY TREATMENT, 2025-2035 (USD Billion)
    26. Rest of South America MARKET SIZE ESTIMATES; FORECAST
      1. BY DISEASE TYPE, 2025-2035 (USD Billion)
      2. BY AGE, 2025-2035 (USD Billion)
      3. BY INDICATION, 2025-2035 (USD Billion)
      4. BY TREATMENT, 2025-2035 (USD Billion)
    27. MEA MARKET SIZE ESTIMATES; FORECAST
      1. BY DISEASE TYPE, 2025-2035 (USD Billion)
      2. BY AGE, 2025-2035 (USD Billion)
      3. BY INDICATION, 2025-2035 (USD Billion)
      4. BY TREATMENT, 2025-2035 (USD Billion)
    28. GCC Countries MARKET SIZE ESTIMATES; FORECAST
      1. BY DISEASE TYPE, 2025-2035 (USD Billion)
      2. BY AGE, 2025-2035 (USD Billion)
      3. BY INDICATION, 2025-2035 (USD Billion)
      4. BY TREATMENT, 2025-2035 (USD Billion)
    29. South Africa MARKET SIZE ESTIMATES; FORECAST
      1. BY DISEASE TYPE, 2025-2035 (USD Billion)
      2. BY AGE, 2025-2035 (USD Billion)
      3. BY INDICATION, 2025-2035 (USD Billion)
      4. BY TREATMENT, 2025-2035 (USD Billion)
    30. Rest of MEA MARKET SIZE ESTIMATES; FORECAST
      1. BY DISEASE TYPE, 2025-2035 (USD Billion)
      2. BY AGE, 2025-2035 (USD Billion)
      3. BY INDICATION, 2025-2035 (USD Billion)
      4. BY TREATMENT, 2025-2035 (USD Billion)
    31. PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
    32. ACQUISITION/PARTNERSHIP

Mild Cognitive Impairment Market Segmentation

Mild Cognitive Impairment Disease Type Outlook (USD Billion, 2019-2032)

  • Amnestic MCI
  • Non-Amnestic MCI

Mild Cognitive Impairment Age Outlook (USD Billion, 2019-2032)

  • Child
  • Adult
  • Geriatric

Mild Cognitive Impairment Market Indication Outlook (USD Billion, 2019-2032)

  • Lewy Body Dementia
  • Parkinson's Disease Dementia
  • Alzheimer’s Disease
  • Vascular Dementia
  • Others

Mild Cognitive Impairment Treatment Outlook (USD Billion, 2019-2032)

  • Medication
    • Cholinesterase Inhibitors
    • Benzodiazepines
    • Glutamate Inhibitors
    • Antihistamines
    • Mao Inhibitors
    • Proton Pump Inhibitors
  • Therapy
    • Cognitive Stimulation Therapy
    • Cognitive Behavioural Therapy (CBT)

Mild Cognitive Impairment Regional Outlook (USD Billion, 2019-2032)

  • North America Outlook (USD Billion, 2019-2032)
    • North America Mild Cognitive Impairment by Disease Type
      • Amnestic MCI
      • Non-Amnestic MCI

 

  • North America Mild Cognitive Impairment by Age
  • Child
  • Adult
  • Geriatric
  • North America Mild Cognitive Impairment Market by Indication
  • Lewy Body Dementia
  • Parkinson's Disease Dementia
  • Alzheimer’s Disease
  • Vascular Dementia
    • Others
  • North America Mild Cognitive Impairment by Treatment
    • Medication
      • Cholinesterase Inhibitors
      • Benzodiazepines
      • Glutamate Inhibitors
      • Antihistamines
      • Mao Inhibitors
      • Proton Pump Inhibitors
    • Therapy
      • Cognitive Stimulation Therapy
      • Cognitive Behavioural Therapy (CBT)

 

 

  • US Outlook (USD Billion, 2019-2032)
  • US Mild Cognitive Impairment by Disease Type
    • Amnestic MCI
    • Non-Amnestic MCI

 

  • US Mild Cognitive Impairment by Age
  • Child
  • Adult
  • Geriatric
  • US Mild Cognitive Impairment Market by Indication
  • Lewy Body Dementia
  • Parkinson's Disease Dementia
  • Alzheimer’s Disease
  • Vascular Dementia
    • Others
  • US Mild Cognitive Impairment by Treatment
    • Medication
      • Cholinesterase Inhibitors
      • Benzodiazepines
      • Glutamate Inhibitors
      • Antihistamines
      • Mao Inhibitors
      • Proton Pump Inhibitors
    • Therapy
      • Cognitive Stimulation Therapy
      • Cognitive Behavioural Therapy (CBT)

 

  • Canada Outlook (USD Billion, 2019-2032)
  • Canada Mild Cognitive Impairment by Disease Type
    • Amnestic MCI
    • Non-Amnestic MCI

 

  • Canada Mild Cognitive Impairment by Age
  • Child
  • Adult
  • Geriatric
  • Canada Mild Cognitive Impairment Market by Indication
  • Lewy Body Dementia
  • Parkinson's Disease Dementia
  • Alzheimer’s Disease
  • Vascular Dementia
  • Others
  • Canada Mild Cognitive Impairment by Treatment
    • Medication
      • Cholinesterase Inhibitors
      • Benzodiazepines
      • Glutamate Inhibitors
      • Antihistamines
      • Mao Inhibitors
      • Proton Pump Inhibitors
    • Therapy
      • Cognitive Stimulation Therapy
        • Cognitive Behavioural Therapy (CBT)
      • Europe Outlook (USD Billion, 2019-2032)
      • Europe Mild Cognitive Impairment by Disease Type
        • Amnestic MCI
        • Non-Amnestic MCI

 

  • Europe Mild Cognitive Impairment by Age
  • Child
  • Adult
  • Geriatric
  • Europe Mild Cognitive Impairment Market by Indication
  • Lewy Body Dementia
  • Parkinson's Disease Dementia
  • Alzheimer’s Disease
  • Vascular Dementia
    • Others
  • Europe Mild Cognitive Impairment by Treatment
    • Medication
      • Cholinesterase Inhibitors
      • Benzodiazepines
      • Glutamate Inhibitors
      • Antihistamines
      • Mao Inhibitors
      • Proton Pump Inhibitors
    • Therapy
      • Cognitive Stimulation Therapy
      • Cognitive Behavioural Therapy (CBT)
    • Germany Outlook (USD Billion, 2019-2032)
    • Germany Mild Cognitive Impairment by Disease Type
      • Amnestic MCI
      • Non-Amnestic MCI

 

  • Germany Mild Cognitive Impairment by Age
  • Child
  • Adult
  • Geriatric
  • Germany Mild Cognitive Impairment Market by Indication
  • Lewy Body Dementia
  • Parkinson's Disease Dementia
  • Alzheimer’s Disease
  • Vascular Dementia
    • Others
  • Germany Mild Cognitive Impairment by Treatment
    • Medication
      • Cholinesterase Inhibitors
      • Benzodiazepines
      • Glutamate Inhibitors
      • Antihistamines
      • Mao Inhibitors
      • Proton Pump Inhibitors
    • Therapy
      • Cognitive Stimulation Therapy
      • Cognitive Behavioural Therapy (CBT)
    • France Outlook (USD Billion, 2019-2032)
    • France Mild Cognitive Impairment by Disease Type
      • Amnestic MCI
      • Non-Amnestic MCI

 

  • France Mild Cognitive Impairment by Age
  • Child
  • Adult
  • Geriatric
  • France Mild Cognitive Impairment Market by Indication
  • Lewy Body Dementia
  • Parkinson's Disease Dementia
  • Alzheimer’s Disease
  • Vascular Dementia
    • Others
  • France Mild Cognitive Impairment by Treatment
    • Medication
      • Cholinesterase Inhibitors
      • Benzodiazepines
      • Glutamate Inhibitors
      • Antihistamines
      • Mao Inhibitors
      • Proton Pump Inhibitors
    • Therapy
      • Cognitive Stimulation Therapy
      • Cognitive Behavioural Therapy (CBT)
    • Italy Outlook (USD Billion, 2019-2032)
    • Italy Mild Cognitive Impairment by Disease Type
      • Amnestic MCI
      • Non-Amnestic MCI

 

  • Italy Mild Cognitive Impairment by Age
  • Child
  • Adult
  • Geriatric
  • Italy Mild Cognitive Impairment Market by Indication
  • Lewy Body Dementia
  • Parkinson's Disease Dementia
  • Alzheimer’s Disease
  • Vascular Dementia
    • Others
  • Italy Mild Cognitive Impairment by Treatment
    • Medication
      • Cholinesterase Inhibitors
      • Benzodiazepines
      • Glutamate Inhibitors
      • Antihistamines
      • Mao Inhibitors
      • Proton Pump Inhibitors
    • Therapy
      • Cognitive Stimulation Therapy
      • Cognitive Behavioural Therapy (CBT)
    • Spain Outlook (USD Billion, 2019-2032)
    • Spain Mild Cognitive Impairment by Disease Type
      • Amnestic MCI
      • Non-Amnestic MCI

 

  • Spain Mild Cognitive Impairment by Age
  • Child
  • Adult
  • Geriatric
  • Spain Mild Cognitive Impairment Market by Indication
  • Lewy Body Dementia
  • Parkinson's Disease Dementia
  • Alzheimer’s Disease
  • Vascular Dementia
    • Others
  • Spain Mild Cognitive Impairment by Treatment
    • Medication
      • Cholinesterase Inhibitors
      • Benzodiazepines
      • Glutamate Inhibitors
      • Antihistamines
      • Mao Inhibitors
      • Proton Pump Inhibitors
    • Therapy
      • Cognitive Stimulation Therapy
      • Cognitive Behavioural Therapy (CBT)
    • Rest of Europe Outlook (USD Billion, 2019-2032)
    • Rest of Europe Mild Cognitive Impairment by Disease Type
      • Amnestic MCI
      • Non-Amnestic MCI

 

  • Rest of Europe Mild Cognitive Impairment by Age
  • Child
  • Adult
  • Geriatric
  • Rest of Europe Mild Cognitive Impairment Market by Indication
  • Lewy Body Dementia
  • Parkinson's Disease Dementia
  • Alzheimer’s Disease
  • Vascular Dementia
    • Others
  • Rest of Europe Mild Cognitive Impairment by Treatment
    • Medication
      • Cholinesterase Inhibitors
      • Benzodiazepines
      • Glutamate Inhibitors
      • Antihistamines
      • Mao Inhibitors
      • Proton Pump Inhibitors
    • Therapy
      • Cognitive Stimulation Therapy
      • Cognitive Behavioural Therapy (CBT)
    • Asia-Pacific Outlook (USD Billion, 2019-2032)
      • Asia-Pacific Mild Cognitive Impairment by Disease Type
        • Amnestic MCI
        • Non-Amnestic MCI

 

  • Asia-Pacific Mild Cognitive Impairment by Age
  • Child
  • Adult
  • Geriatric
  • Asia-Pacific Mild Cognitive Impairment Market by Indication
  • Lewy Body Dementia
  • Parkinson's Disease Dementia
  • Alzheimer’s Disease
  • Vascular Dementia
    • Others
  • Asia-Pacific Mild Cognitive Impairment by Treatment
    • Medication
      • Cholinesterase Inhibitors
      • Benzodiazepines
      • Glutamate Inhibitors
      • Antihistamines
      • Mao Inhibitors
      • Proton Pump Inhibitors
    • Therapy
      • Cognitive Stimulation Therapy
      • Cognitive Behavioural Therapy (CBT)
    • China Outlook (USD Billion, 2019-2032)
    • China Mild Cognitive Impairment by Disease Type
      • Amnestic MCI
      • Non-Amnestic MCI

 

  • China Mild Cognitive Impairment by Age
  • Child
  • Adult
  • Geriatric
  • China Mild Cognitive Impairment Market by Indication
  • Lewy Body Dementia
  • Parkinson's Disease Dementia
  • Alzheimer’s Disease
  • Vascular Dementia
  • Others
  • China Mild Cognitive Impairment by Treatment
    • Medication
      • Cholinesterase Inhibitors
      • Benzodiazepines
      • Glutamate Inhibitors
      • Antihistamines
      • Mao Inhibitors
      • Proton Pump Inhibitors
    • Therapy
      • Cognitive Stimulation Therapy
      • Cognitive Behavioural Therapy (CBT)

 

 

  • Japan Outlook (USD Billion, 2019-2032)
  • Japan Mild Cognitive Impairment by Disease Type
    • Amnestic MCI
    • Non-Amnestic MCI

 

  • Japan Mild Cognitive Impairment by Age
  • Child
  • Adult
  • Geriatric
  • Japan Mild Cognitive Impairment Market by Indication
  • Lewy Body Dementia
  • Parkinson's Disease Dementia
  • Alzheimer’s Disease
  • Vascular Dementia
  • Others
  • Japan Mild Cognitive Impairment by Treatment
    • Medication
      • Cholinesterase Inhibitors
      • Benzodiazepines
      • Glutamate Inhibitors
      • Antihistamines
      • Mao Inhibitors
      • Proton Pump Inhibitors
    • Therapy
      • Cognitive Stimulation Therapy
      • Cognitive Behavioural Therapy (CBT)
    • India Outlook (USD Billion, 2019-2032)
    • India Mild Cognitive Impairment by Disease Type
      • Amnestic MCI
      • Non-Amnestic MCI

 

  • India Mild Cognitive Impairment by Age
  • Child
  • Adult
  • Geriatric
  • India Mild Cognitive Impairment Market by Indication
  • Lewy Body Dementia
  • Parkinson's Disease Dementia
  • Alzheimer’s Disease
  • Vascular Dementia
  • Others
  • India Mild Cognitive Impairment by Treatment
    • Medication
      • Cholinesterase Inhibitors
      • Benzodiazepines
      • Glutamate Inhibitors
      • Antihistamines
      • Mao Inhibitors
      • Proton Pump Inhibitors
    • Therapy
      • Cognitive Stimulation Therapy
      • Cognitive Behavioural Therapy (CBT)
    • South Korea Outlook (USD Billion, 2019-2032)
    • South Korea Mild Cognitive Impairment by Disease Type
      • Amnestic MCI
      • Non-Amnestic MCI

 

  • South Korea Mild Cognitive Impairment by Age
  • Child
  • Adult
  • Geriatric
  • South Korea Mild Cognitive Impairment Market by Indication
  • Lewy Body Dementia
  • Parkinson's Disease Dementia
  • Alzheimer’s Disease
  • Vascular Dementia
  • Others
  • South Korea Mild Cognitive Impairment by Treatment
    • Medication
      • Cholinesterase Inhibitors
      • Benzodiazepines
      • Glutamate Inhibitors
      • Antihistamines
      • Mao Inhibitors
      • Proton Pump Inhibitors
    • Therapy
      • Cognitive Stimulation Therapy
        • Cognitive Behavioural Therapy (CBT)

 

  • Australia Outlook (USD Billion, 2019-2032)
  • Australia Mild Cognitive Impairment by Disease Type
    • Amnestic MCI
    • Non-Amnestic MCI

 

  • Australia Mild Cognitive Impairment by Age
  • Child
  • Adult
  • Geriatric
  • Australia Mild Cognitive Impairment Market by Indication
  • Lewy Body Dementia
  • Parkinson's Disease Dementia
  • Alzheimer’s Disease
  • Vascular Dementia
  • Others
  • Australia Mild Cognitive Impairment by Treatment
    • Medication
      • Cholinesterase Inhibitors
      • Benzodiazepines
      • Glutamate Inhibitors
      • Antihistamines
      • Mao Inhibitors
      • Proton Pump Inhibitors
    • Therapy
      • Cognitive Stimulation Therapy
      • Cognitive Behavioural Therapy (CBT)
    • Rest of the World Outlook (USD Billion, 2019-2032)
      • Rest of the World Mild Cognitive Impairment by Disease Type
        • Amnestic MCI
        • Non-Amnestic MCI

 

  • Rest of the World Mild Cognitive Impairment by Age
  • Child
  • Adult
  • Geriatric
  • Rest of the World Mild Cognitive Impairment Market by Indication
  • Lewy Body Dementia
  • Parkinson's Disease Dementia
  • Alzheimer’s Disease
  • Vascular Dementia
    • Others
  • Rest of the World Mild Cognitive Impairment by Treatment
    • Medication
      • Cholinesterase Inhibitors
      • Benzodiazepines
      • Glutamate Inhibitors
      • Antihistamines
      • Mao Inhibitors
      • Proton Pump Inhibitors
    • Therapy
      • Cognitive Stimulation Therapy
      • Cognitive Behavioural Therapy (CBT)
    • Middle East and Africa Outlook (USD Billion, 2019-2032)
    • Middle East and Africa Mild Cognitive Impairment by Disease Type
      • Amnestic MCI
      • Non-Amnestic MCI

 

  • Middle East and Africa Mild Cognitive Impairment by Age
  • Child
  • Adult
  • Geriatric
  • Middle East and Africa Mild Cognitive Impairment Market by Indication
  • Lewy Body Dementia
  • Parkinson's Disease Dementia
  • Alzheimer’s Disease
  • Vascular Dementia
    • Others
  • Middle East and Africa Mild Cognitive Impairment by Treatment
    • Medication
      • Cholinesterase Inhibitors
      • Benzodiazepines
      • Glutamate Inhibitors
      • Antihistamines
      • Mao Inhibitors
      • Proton Pump Inhibitors
    • Therapy
      • Cognitive Stimulation Therapy
        • Cognitive Behavioural Therapy (CBT)
      • South America Outlook (USD Billion, 2019-2032)
      • South America Mild Cognitive Impairment by Disease Type
        • Amnestic MCI
        • Non-Amnestic MCI

 

  • South America Mild Cognitive Impairment by Age
  • Child
  • Adult
  • Geriatric
  • South America Mild Cognitive Impairment Market by Indication
  • Lewy Body Dementia
  • Parkinson's Disease Dementia
  • Alzheimer’s Disease
  • Vascular Dementia
    • Others
  • South America Mild Cognitive Impairment by Treatment
    • Medication
      • Cholinesterase Inhibitors
      • Benzodiazepines
      • Glutamate Inhibitors
      • Antihistamines
      • Mao Inhibitors
      • Proton Pump Inhibitors
    • Therapy
      • Cognitive Stimulation Therapy
        • Cognitive Behavioural Therapy (CBT)
Infographic

Free Sample Request

Kindly complete the form below to receive a free sample of this Report

Get Free Sample

Related Reports

Regional Reports
Country Reports

Customer Strories

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Victoria Milne

Founder
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓